Pilot study of administration of psilocybin in healthy volunteers within a marae setting

This interventional trial (n=12) will assess the feasibility and acceptability of administering psilocybin (25mg) to healthy volunteers within a marae setting (Māori) under clinical supervision.

Conducted by the Matai Medical Research Institute and funded by the Health Research Council of New Zealand, this pilot study aims to explore the cultural appropriateness of psilocybin-assisted psychotherapy for Māori populations. The study will incorporate Māori concepts of wairua (spirituality) and tikanga (cultural practice) into the treatment model to enhance the therapeutic environment.

The primary outcomes will be measured through participant recruitment and attrition rates, as well as acceptability gauged via semi-structured interviews one week after psilocybin administration. Participants must be Māori, aged 18-65, and meet specific inclusion criteria, while those with certain psychiatric, substance use, or medical conditions will be excluded.

Recruitment is anticipated to begin in August 2024 and conclude by December 2024. Ethics approval was granted by the Central Health and Disability Ethics Committee in March 2024.

Topic Healthy Subjects Addiction
Compound Psilocybin
Country New Zealand
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.